Systems and methods of the present disclosure include a five-layer environment consisting tremor management hardware, interface, control system, machine learning environment and cloud capabilities. These elements come together to implement program instructions and perform steps to: receive sensory data elements(s) for tremor stat(s), physiological and/or environmental state(s) of the user, user activities and state(s) of the tremor management hardware and based on these state(s) generate at least one actionable tremor mitigation action associated with historical tremor mitigation improvements recorded in a memory, and display at a user computing device the at least one actionable tremor mitigation action to a user, a healthcare provider, or both.

A method, a structure, and a computer system for assessing user mobility. The exemplary embodiments may include collecting mobility data corresponding to a user and extracting one or more low level features from the mobility data. The exemplary embodiments may further include extracting one or more clinical level features from the low level features and assessing one or more health conditions of the user based on applying one or more models to the one or more clinical level features.

The invention provides a gait evaluating system and a gait evaluating method. The gait evaluation system includes a gait evaluating device configured to: obtain, from a pressure detection device, a plurality of pressure values of a user walking on the pressure detection device; obtain a plurality of step feature values of the user based on the pressure values; obtain a plurality of walking limb feature values when the user walks on the pressure detection device based on a sensing data provided by a limb sensing device; and evaluate a gait of the user based on the step feature values and the walking limb feature values.

Provided herein are methods and systems for high-resolution, cerebrospinal fluid-suppressed T2*-weighted magnetic resonance imaging of cortical lesions.

The present invention relates to methods for tuning treatment parameters in movement disorder therapy systems. The present invention further relates to a system for screening patients to determine viability as candidates for certain therapy modalities, such as deep brain stimulation (DBS). The present invention still further provides methods of quantifying movement disorders for the treatment of patients who exhibit symptoms of such movement disorders including, but not limited to, Parkinson's disease and Parkinsonism, Dystonia, Chorea, and Huntington's disease, Ataxia, Tremor and Essential Tremor, Tourette syndrome, stroke, and the like. The present invention yet further relates to methods of tuning a therapy device using objective quantified movement disorder symptom data acquired by a movement disorder diagnostic device to determine the therapy setting or parameters to be provided to the subject via his or her therapy device. The present invention also provides treatment and tuning remotely, allowing for home monitoring of subjects.

A system includes processing circuitry configured to determine, for each electrode combination of a plurality of electrode combinations, a metric based on a sensed electrical signal from the electrode combination. The processing circuitry is further configured to determine, for each electrode of a plurality of electrodes, a subset of electrode combinations of the plurality of electrode combinations, each electrode combination of the subset of electrode combinations comprising the electrode, wherein the subset of electrode combinations comprises at least two electrode combinations. The processing circuitry is further configured to determine, for each electrode of the plurality of electrodes, a composite metric based on the metrics of the subset of electrode combinations. The processing circuitry is further configured to determine, select, based on the composite metrics of the plurality of electrodes, at least one electrode for at least one of sensing electrical signals or delivering electrical stimulation.

A method of determining brain stimulation parameters includes applying Low Frequency Stimulation (LFS) to a contact of a multi-contact electrode implanted in a target structure in an individual's brain. Evoked Compound Activity (ECA) evoked in the target structure by the LFS is measured. A range of frequencies for delivering brain stimulation within a predetermined range based on a phase space extracted from the ECA is determined. Stimulation frequencies are applied to the contact of the multi-contact electrode within the determined range of frequencies. High Frequency Oscillations (HFO) evoked in the target structure by the applied stimulation frequencies within the determined range are measured. A frequency evoking HFO above a predetermined threshold is determined. The determined frequency is selected as a treatment frequency for the target structure.

A method of locating an implantation site in the brain includes inserting a plurality of multi-contact electrodes into a region of a target structure in an individual's brain. High Frequency Stimulation (HFS) is applied to a contact of a multi-contact electrode of the plurality of multi-contact electrodes. High Frequency Oscillations (HFO) evoked in the region of the target structure by the HFS are measured. Evoked Compound Activity (ECA) evoked in the region of the target structure by the HFS is measured. It is determined if at least one of the HFO and the ECA is above a predetermined threshold. If at least one of the HFO and the ECA is above the predetermined threshold, a location of the contact of the multi-contact electrode is identified as a site for electrode implantation in the individual's brain.

Delivery of electrical stimulation to the substantia nigra and the subthalamic nucleus of a brain of a patient are independently controlled in order to treat sleep and movement disorders. Electrical stimulation of the subthalamic nucleus may be effective in treating symptoms associated with a movement disorder, and electrical stimulation of the substantia nigra may be effective in treating symptoms associated with a sleep disorder. During a sleep state of the patient, a sleep stage of the patient may be determined, and an electrical stimulation device may be controlled based on the determined sleep stage. Electrical stimulation of the substantia nigra and subthalamic nucleus may be delivered at substantially the same time or at different times.

A method of diagnosing and monitoring biologic dysfunction may include performing measurements utilizing sensors of wireless earpieces, analyzing the measurements, comparing the measurements to established norms, determining whether the measurements indicate biologic dysfunction. The measurements may include biologic data of a user or environmental data. The sensors may include inertial sensors or optical sensors. The biologic dysfunction may include neurologic dysfunction and the neurologic dysfunction may include intention tremor. The method may include reporting the biologic dysfunction to a user.